EUVIMEDEUVIMED entdecken
Crossref

Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial

Martin Schuler, Donald A. Berry, Howard A. Burris, Daniel D. Von Hoff, Michelle A. Detry, Kert Viele, Sebastian Ochsenreither, David Spigel, Timothy Larson, Fadi Kayali, Lee Schwartzberg, Anna L. Illert und 5 weitere

JCO Oncology Advances · 2024-11 · (1)

DOI: 10.1200/oa-24-00044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2024-11. Verfasst von Martin Schuler und 16 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To report on CheckMate 627 (ClinicalTrials.gov identifier: NCT02832167 ), a phase II adaptive basket design trial of nivolumab in uncommon advanced/metastatic tumors. METHODS Adults with previously treated advanced/metastatic malignancies received nivolumab 240 mg once every 2 weeks for eight cycles, followed by nivolumab 480 mg once every 4 weeks. The primary end point was investigator-assessed objective response rate (ORR). In addition to observed ORRs, model-adjusted ORRs were estimated via Bayesian analysis in patients who completed ≥28 weeks of follow-up, to correct for variability inherent in multitumor studies. This adaptive model allowed for borrowing of information from other tumors demonstrating similar ORR and evaluation of nivolumab treatment effect versus historical standard-of-care (SOC) controls. Nivolumab was considered to have met the criteria for ORR superiority in a group if there was ≥80% posterior probability of ORR with nivolumab exceeding ORR with historical SOC control treatment in that group. RESULTS The study included 25 tumor groups (n = 239), with 24 groups included in the Bayesian ORR analysis (efficacy was reported but not modeled in the other group that contained a mix of tumor types). The poorly differentiated neuroendocrine tumor (PD-NET) group (n = 20) met the prespecified criterion for ORR superiority with a 93% probability of the model-adjusted ORR with nivolumab (22% [95% CI, 8 to 44]) exceeding the respective historical SOC ORR of 10.0%. The observed ORR was 30.0% (95% CI, 11.9 to 54.3). There were no new safety signals for nivolumab. CONCLUSION Nivolumab showed evidence of antitumor activity in patients with advanced/metastatic PD-NET in CheckMate 627. The results of this study support the use of an adaptive basket design for identification of rare cancers responsive to immunotherapy.

Zitieren

APA

Schuler, M., Berry, D. A., Burris, H. A., Hoff, D. D. V., Detry, M. A., Viele, K., Ochsenreither, S., Spigel, D., Larson, T., Kayali, F., Schwartzberg, L., Illert, A. L., Khan, T. A., Soskind, R., Lee, M., Forslund, A., & Naing, A. (2024). Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial. JCO Oncology Advances. https://doi.org/10.1200/oa-24-00044

Vancouver

Schuler M, Berry DA, Burris HA, Hoff DDV, Detry MA, Viele K, et al. Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial. JCO Oncology Advances. 2024. doi:10.1200/oa-24-00044

BibTeX
@article{Schuler2024,
  author = {Schuler, Martin and Berry, Donald A. and Burris, Howard A. and Hoff, Daniel D. Von and Detry, Michelle A. and Viele, Kert and Ochsenreither, Sebastian and Spigel, David and Larson, Timothy and Kayali, Fadi and Schwartzberg, Lee and Illert, Anna L. and Khan, Tariq Aziz and Soskind, Rose and Lee, Michelle and Forslund, Ann and Naing, Aung},
  title = {Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial},
  journal = {JCO Oncology Advances},
  year = {2024},
  number = {1},
  doi = {10.1200/oa-24-00044}
}
Kostenlos starten →